Adma Biologics Inc (ADMA) Company Profile & Statistics

Adma Biologics Inc
ADMA
(Nasdaq - US)
Open
19.36
+0.32 (+1.68%)
in:usd•As of: Nov 18, 2024 12:24 UTC -5
Open
19.02
High
19.43
Low
19.02

About Adma Biologics Inc

CEO

Adam S. Grossman

Headquarters

465 state route 17

ramsey, nj 07446, united states

Auditor

CohnReznick LLP

Employees

624

Share Holders

Website

www.admabiologics.com

Industry

biotechnology

Sector

health technology

Company Overview

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Adma Biologics Inc Statistics

Valuation Measures

Market Capitalization ²	4.58B
Enterprise Value	4.60B
Enterprise Value/EBITDA (ttm)	36.99
Price to Earnings Ratio (ttm)	47.60
Price to Book (mrq)	19.41
Price to Sales (ttm)	11.76
Price to Cash (ytd)	374.67

Profitability

Gross Margin (ttm)	48.30%
Operating Margin (ttm)	24.64%
Profit Margin (ttm)	14.44%
Return on Equity (ttm)	53.20%
Return on Invested Capital (ttm)	19.91%
Return on Assets (ttm)	26.07%

Income Statement

Revenue (ttm)	382.81M
Revenue Per Share (ttm)	1.62
Gross Profit (ttm)	187.31M
EBITDA (ttm)³	124.39M
Net Income Avi to Common (ttm)	68.13M
Diluted EPS (ttm)	0.28

Share Statistics

Beta (5Y Monthly)	0.64
52-Week Change	380.40%
S&P500 52-Week Change	29.59%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	236.39M
Dividend Yield	0.00%
Float ⁴	227.64M
% Held by Insiders	3.70%
% Held by Institutions	75.68%

Balance Sheet

Total Cash (mrq)	86.71M
Total Cash Per Share (mrq)	0.37
Total Debt (mrq)	111.38M
Total Debt/Equity (mrq)	48.03%
Current Ratio (mrq)	7.09%
Quick Ratio (mrq)	3.26%
Book Value Per Share (mrq)	0.98

Cash Flow

Operating Cash Flow Per Share (ytd)	0.28
Free Cash Flow (ytd)	62.99M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Adma Biologics Inc

Trade With A Regulated Broker